Open Nav

Please submit your session questions in advance at

ProterixBio, Inc

  • Michael Miller, ProterixBio, Inc

ProterixBio is a provider of molecular assessments to transform the care of patients with chronic respiratory disease. Our initial focus is COPD, which is the 3rd leading cause of death worldwide and contributes >$40B of direct healthcare spending annually in the U.S. alone. ProterixBio’s proprietary technology uses multiple blood-based biomarkers combined in an algorithm to characterize a patient’s disease state. Results from multiple clinical studies presented major respiratory conferences demonstrate improvement over symptoms and history alone for assessing propensity for future exacerbations. We are starting pilot studies with COPD management programs to target patient enrollment with the ultimate goal of reducing the number of ER visits and hospitalizations. The rapid expansion of value-based care programs managing chronically ill populations and the emergence of new targeted therapies within respiratory provide substantial opportunity for growth.

  • Date:Tuesday, February 12
  • Time:1:45 PM - 2:00 PM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23396
  • Goal for Presentation:Provide visibility for ProterixBio to investors and potential partners
  • Company Website:
  • Company HQ City:Billerica
  • Company HQ State:Massachusetts
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$20M
  • Previous and Current Investors:New Science Ventures, Morningside
  • CEO/Top Company Official:Michael Miller
  • Year Founded:2016
  • Main Therapeutic Focus:Respiratory
  • Lead Product in Development:COPD Stratification Test
  • Development Phase of Primary Product:Other/Not Applicable
Michael Miller
ProterixBio, Inc